Table 2.
Recent studies with specific regimen for patients over 60 years with HL.
| Study | Nb pts | Age | Protocol | Response | Survival | Toxicity | Comments | Ref |
|---|---|---|---|---|---|---|---|---|
| Macpherson (2002) | 38 | > 65 med 72 | ODBEP | NR | 5y OS 42% | no toxic death | radiotherapy for bulky med. | 53 |
| Levis (2004) | 105 | > 65 mean 71 | VEPEMB | CR IIA 98% IIB–IV 58% |
5y RFS IIA 95 % IIB–IV 61% |
TRM 2% | pronostic value of “comorbidity” | 48 |
| Kolstad (2007) | 29 | ≥ 60 med 71 | CHOP 21 stage I–IIA 2–4+Rt stage IIB–III 6–8 + RT |
CR 93% | stage I–IIA 3y OS 91% 3y PFS 82% stage IIB–IV 3y OS 67% 3y PFS 72% |
2 tox. deaths | 55% with comorbidities | 18 |
| Halbsguth (2010) | 60 | 60–75 med 68 | BACOPP 6–8 cycles | CR/CRU 85 % | 3Y PFS 60% 3Y OS 71% |
TRM 12% grade 3–4 87 % |
radiotherapy for “residual mass” | 50 |
| Böll (2011) | 59 | 60–75 med 66,7 | PVAG | CR/CRU 78% | 3Y PFS 58 % 3Y OS 66% |
1 tox. death grade 3–4 75 % |
radiotherapy for “residual mass” | 49 |
| Proctor (2012) | 103 | > 60 med 73 | VEPEMB stage I–IIA 3+Rt stage IIB–III 6+ RT |
stage I–IIA 74% CR stage IIB–IV 61% CR |
stage I–IIA 3y OS 81% 3y PFS 74% stage IIB–IV 3y OS 66% 3y PFS 58% |
TRM 7% | non frail patients only | 46 |